Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb publishes positive trial data for diabetes drug

Bristol-Myers Squibb publishes positive trial data for diabetes drug

21st September 2010

Bristol-Myers Squibb has published new phase III clinical trial data supporting the benefits its investigational drug dapagliflozin can bring to type 2 diabetes patients.

The company, in association with partner AstraZeneca, has conducted a study in which the treatment was combined with glimepiride therapy, with the aim of helping to reduce glycosylated haemoglobin levels.

It was found that the combination therapy delivered superior performance according to this measure compared to glimepiride alone, while also providing improvements in terms of body weight, oral glucose tolerance and fasting plasma glucose.

Krzysztof Strojek, a professor at the Silesian Medical University in Poland and principal investigator of the study, said this means the drug could play a role in eliminating the progressive deterioration of glycaemic control often seen in patients, which usually requires the use of additional drug therapy.

Last month, Bristol-Myers Squibb and Pfizer attended the European Society of Cardiology Congress 2010 in order to present new clinical data on apixaban, a treatment for atrial fibrillation.ADNFCR-8000103-ID-800073766-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.